Table 1.

Patient demographics and clinical characteristics

CharacteristicN (%)
Age, y
 Median63
 Range44–90
Female sex26 (65)
Stage at diagnosis
 IIIA2 (5)
 IIIB4 (10)
 IV34 (85)
EGFR-sensitizing mutation
 Exon 19 deletion29 (73)
 L858R8 (20)
 Othera3 (8)
Most recent treatment regimen
 Single-agent erlotinib18 (45)
 Single-agent afatanib3 (8)
 Erlotinib plus chemotherapy11 (28)
 Erlotinib plus bevacizumab3 (8)
 Afatanib plus cetuximab1 (3)
 Chemotherapy4 (10)
  • aIncluding G719C, E709K, and E709A+G719C.